United Homes Group stock plunges after Nikki Haley, directors resign
Investing.com -- A newly appointed panel of U.S. vaccine advisers will vote on flu shots containing thimerosal and discuss recommendations for a combination measles shot at an upcoming meeting.
The advisers to the Centers for Disease Control and Prevention will meet on June 25 and 26 to vote on who should receive shots for respiratory syncytial virus and influenza, according to a draft agenda on the CDC website.
This meeting follows Health Secretary Robert F. Kennedy Jr.’s recent appointment of eight new members to the key vaccine advisory panel after firing all 17 previous members of the independent expert committee.
The new panel will review whether a shot that prevents measles, mumps, rubella, and varicella (MMRV) should be given to children under 5 years old.
The agenda did not specify who will present data on MMRV or thimerosal, a mercury-based preservative used for decades in multi-dose vaccine vials.
According to the CDC, there is no evidence of harm from the low doses of thimerosal in vaccines beyond minor reactions like redness and swelling at injection sites.
Kennedy has promoted doubts about vaccine safety for decades, including claims of a link between vaccines and autism that scientific evidence has debunked. He has requested a review of all data for the measles shot, which is considered the most effective way to prevent the highly contagious and potentially deadly virus.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.